Virax Biolabs Group Limited Ordinary Shares (VRAX) - Total Liabilities
Based on the latest financial reports, Virax Biolabs Group Limited Ordinary Shares (VRAX) has total liabilities worth $641.52K USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Virax Biolabs Group Limited Ordinary Sha liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Virax Biolabs Group Limited Ordinary Shares - Total Liabilities Trend (2020–2025)
This chart illustrates how Virax Biolabs Group Limited Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see VRAX total asset value.
Virax Biolabs Group Limited Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of Virax Biolabs Group Limited Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bridge Saas Ltd
AU:BGE
|
Australia | AU$1.67 Million |
|
GCP Asset Backed Income Fund Limited
LSE:GABI
|
UK | GBX590.00K |
|
CT UK High Income Ord
LSE:CHI
|
UK | GBX21.38 Million |
|
Dixie Gold Inc
V:DG
|
Canada | CA$8.00K |
|
Baumart Holdings Ltd
AU:BMH
|
Australia | AU$1.10 Million |
|
Scinai Immunotherapeutics Ltd
NASDAQ:SCNI
|
USA | $5.83 Million |
|
Peel Hunt Ltd
LSE:PEEL
|
UK | GBX641.21 Million |
|
Investment Friends Capital SE
WAR:IFC
|
Poland | zł1.84 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Virax Biolabs Group Limited Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See VRAX net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Virax Biolabs Group Limited Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Virax Biolabs Group Limited Ordinary Shares (2020–2025)
The table below shows the annual total liabilities of Virax Biolabs Group Limited Ordinary Shares from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $964.75K | +179.48% |
| 2024-03-31 | $345.19K | -62.00% |
| 2023-03-31 | $908.40K | -27.06% |
| 2022-03-31 | $1.25 Million | +42.92% |
| 2021-03-31 | $871.43K | -29.59% |
| 2020-03-31 | $1.24 Million | -- |
About Virax Biolabs Group Limited Ordinary Shares
Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, ot… Read more